These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1905778)

  • 1. Implication of thromboxane in the pathogenesis of Kawasaki disease and a suggestion for using novel thromboxane synthetase inhibitors in its treatment.
    Backon J
    Med Hypotheses; 1991 Mar; 34(3):230-1. PubMed ID: 1905778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet immune complex interaction in pathogenesis of Kawasaki disease and childhood polyarteritis.
    Levin M; Holland PC; Nokes TJ; Novelli V; Mola M; Levinsky RJ; Dillon MJ; Barratt TM; Marshall WC
    Br Med J (Clin Res Ed); 1985 May; 290(6480):1456-60. PubMed ID: 3922532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kawasaki syndrome.
    Wortmann DW
    Semin Dermatol; 1992 Mar; 11(1):37-47. PubMed ID: 1550715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet immune complex interaction in the pathogenesis of Kawasaki disease.
    Levin M; Holland PC; Novelli V
    Prog Clin Biol Res; 1987; 250():227-37. PubMed ID: 3423040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry.
    Backon J
    Med Hypotheses; 1986 Jul; 20(3):271-8. PubMed ID: 3528776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease.
    Zaitsu M; Hamasaki Y; Tashiro K; Matsuo M; Ichimaru T; Fujita I; Tasaki H; Miyazaki S
    J Infect Dis; 2000 Mar; 181(3):1101-9. PubMed ID: 10720537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of thromboxanes in gastrointestinal physiopathology.
    Bennett TA
    Int J Tissue React; 1983; 5(3):237-9. PubMed ID: 6686219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combined thromboxane synthetase inhibition/thromboxane receptor antagonism in two models of sudden cardiac death in the canine: limited role for thromboxane.
    Kitzen JM; Chi LG; Uprichard AC; Lucchesi BR
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):68-80. PubMed ID: 1696668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental coronary artery thrombosis in the absence of thromboxane A2 synthesis: evidence for alternate pathways for coronary thrombosis.
    Hook BG; Schumacher WA; Lee DL; Jolly SR; Lucchesi BR
    J Cardiovasc Pharmacol; 1985; 7(1):174-81. PubMed ID: 2580139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kawasaki disease: etiopathogenesis and novel treatment strategies.
    Agarwal S; Agrawal DK
    Expert Rev Clin Immunol; 2017 Mar; 13(3):247-258. PubMed ID: 27590181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rupture of a giant coronary artery aneurysm due to Kawasaki disease.
    Hwong TM; Arifi AA; Wan IY; Thung KH; Wan S; Sung RY; Yim AP
    Ann Thorac Surg; 2004 Aug; 78(2):693-5. PubMed ID: 15276552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetyl glycerylphosphorylcholine inhibition of prostaglandin I2-stimulated adenosine 3',5'-cyclic monophosphate levels in human platelets. Evidence for thromboxane A2 dependence.
    Miller OV; Ayer DE; Gorman RR
    Biochim Biophys Acta; 1982 Jun; 711(3):445-51. PubMed ID: 6285985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
    Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
    Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease.
    Hidaka T; Nakano M; Ueta T; Komatsu Y; Yamamoto M
    J Pediatr; 1983 Jan; 102(1):94-6. PubMed ID: 6401332
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation.
    Nicolaou KC; Magolda RL; Smith JB; Aharony D; Smith EF; Lefer AM
    Proc Natl Acad Sci U S A; 1979 Jun; 76(6):2566-70. PubMed ID: 288046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolongation of experimental cardiac allograft survival with thromboxane-related drugs.
    Foegh ML; Khirabadi B; Ramwell PW
    Transplantation; 1985 Aug; 40(2):124-5. PubMed ID: 3161224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cytomegalovirus infection, atypical Kawasaki disease, and coronary aneurysms in 2 infants.
    Catalano-Pons C; Quartier P; Leruez-Ville M; Kaguelidou F; Gendrel D; Lenoir G; Casanova JL; Bonnet D
    Clin Infect Dis; 2005 Sep; 41(5):e53-6. PubMed ID: 16080076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological features of Kawasaki disease (mucocutaneous lymph node syndrome).
    Landing BH; Larson EJ
    Am J Cardiovasc Pathol; 1987; 1(2):218-29. PubMed ID: 3333141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase.
    Smith JB
    Thromb Res; 1982 Nov; 28(4):477-85. PubMed ID: 6891843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of current therapy of Kawasaki disease on eicosanoid metabolism.
    Fulton DR; Meissner C; Peterson MB
    Am J Cardiol; 1988 Jun; 61(15):1323-7. PubMed ID: 2454025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.